2022 Volume 39 Issue 4 Pages 460-463
Multiple System Atrophy (MSA) is a progressive neurodegenerative disease characterized by parkinsonism, autonomic failure, and cerebellar ataxia, with an average course of approximately nine years. Because symptomatic treatment is inefficient, the development of innovative drugs is a worldwide hope. There has been considerable progress in elucidating the structure of α–synuclein in MSA and PD, as well as developing pathophysiological elucidation and differential diagnostic methods based on the structural differences. It is also becoming clear that neuroinflammation and changes in oligodendroglia contribute to the pathogenesis of MSA and PD. In light of these findings, clinical trials of antibody therapy against synuclein, multi–targeted disease–modifying therapies, including mesenchymal stem cell therapies, and various symptomatic therapies steadily have provided new perspectives. We will discuss recent topics in MSA pathophysiology and drug development in this review.
